AERI Aerie Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AERI

Price (delayed)

$15.51

Market cap

$727.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.82

Enterprise value

$834.67M

Highlights
AERI's EPS is up by 13% YoY and by 4.3% from the previous quarter
The net income has grown by 12% year-on-year and by 3.9% since the previous quarter
The gross profit has declined by 13% year-on-year but it has increased by 3.5% since the previous quarter
AERI's equity has dropped by 143% since the previous quarter and by 108% year-on-year
AERI's quick ratio is down by 30% year-on-year and by 4.2% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.aeriepharma.com/
Peers: INSM LXRX ALIM MRK

Key stats

What are the main financial stats of AERI
Market
Shares outstanding
46.89M
Market cap
$727.31M
Enterprise value
$834.67M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
8.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.73
Earnings
Revenue
$85.77M
EBIT
-$170.63M
EBITDA
-$135.74M
Free cash flow
-$55.55M
Per share
EPS
-$3.82
Free cash flow per share
-$1.2
Book value per share
-$0.22
Revenue per share
$1.86
TBVPS
$7.87
Balance sheet
Total assets
$362.73M
Total liabilities
$373.1M
Debt
$230.05M
Equity
-$10.37M
Working capital
$200.21M
Liquidity
Debt to equity
-22.19
Current ratio
3.14
Quick ratio
2.72
Net debt/EBITDA
-0.79
Margins
EBITDA margin
-158.3%
Gross margin
69.8%
Net margin
-205.1%
Operating margin
-170.2%
Efficiency
Return on assets
-46.4%
Return on equity
-430.4%
Return on invested capital
-46%
Return on capital employed
-63.3%
Return on sales
-198.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AERI stock price

How has the Aerie Pharmaceuticals stock price performed over time
Intraday
-0.13%
1 week
1.57%
1 month
-11.32%
1 year
23%
YTD
14.8%
QTD
-3.12%

Financial performance

How have Aerie Pharmaceuticals's revenue and profit performed over time
Revenue
$85.77M
Gross profit
$59.83M
Operating income
-$145.97M
Net income
-$175.94M
Gross margin
69.8%
Net margin
-205.1%
The operating margin has grown by 26% YoY and by 9% from the previous quarter
The operating income is up by 20% year-on-year and by 6% since the previous quarter
AERI's gross margin is down by 19% year-on-year
Aerie Pharmaceuticals's net margin has increased by 19% YoY and by 7% from the previous quarter

Growth

What is Aerie Pharmaceuticals's growth rate over time

Valuation

What is Aerie Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
8.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.73
AERI's EPS is up by 13% YoY and by 4.3% from the previous quarter
AERI's equity has dropped by 143% since the previous quarter and by 108% year-on-year
The company's revenue rose by 8% YoY and by 3.2% QoQ
The price to sales (P/S) is 4.3% more than the last 4 quarters average of 8.0

Efficiency

How efficient is Aerie Pharmaceuticals business performance
Aerie Pharmaceuticals's ROE has plunged by 77% from the previous quarter
The ROIC has grown by 27% YoY and by 2.1% from the previous quarter
AERI's ROS is up by 21% YoY and by 7% from the previous quarter
The ROA has grown by 9% YoY

Dividends

What is AERI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AERI.

Financial health

How did Aerie Pharmaceuticals financials performed over time
Aerie Pharmaceuticals's total assets is 2.8% lower than its total liabilities
The total liabilities has grown by 31% YoY
AERI's quick ratio is down by 30% year-on-year and by 4.2% since the previous quarter
AERI's equity has dropped by 143% since the previous quarter and by 108% year-on-year
Aerie Pharmaceuticals's debt has increased by 9% YoY and by 2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.